ArticlePreventive nutrition and food science2026
Ameliorative Effects of Fermented Gold Kiwi on Reflux Esophagitis in a Rat Model.
Article in Preventive nutrition and food science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reflux esophagitis (RE) is characterized by the backflow of gastric contents, including acid, pepsin, and bile, into the esophagus. Fermented gold kiwi (FGK) has demonstrated protective effects against acute gastritis and efficacy in digestive disorders such as constipation, suggesting its potential potential therapeutic relevance for RE. In this study, we evaluated the protective effects of FGK, fermented with five probiotic strains, including two kiwi-derived stains, in a rats model of acute RE. Male Sprague-Dawley rats (6 weeks old, n=6 per group) were divided into six groups: normal control, negative control (vehicle, Veh), positive control, and FGK-treated groups (50, 125, and 250 mg/kg). After 24 h of fasting, test substances were orally administered, followed by pyloric ligation under isoflurane anesthesia 2 h later. Esophageal tissue and gastric juice were collected 4.5 h post-surgery for analysis. The evaluation parameters included the esophageal damage ratio; pH of the gastric content and pepsin activity; esophageal tissue glutathione (GSH) and malondialdehyde (MDA) levels; inflammatory cytokine expression [tumor necrosis factor-α; interleukin (IL)-1β; and IL-6]; and histological analysis of esophageal mucosa. FGK treatment significantly reduced esophageal damage and improved gastric pH and pepsin activity in a dose-dependent manner, compared to the Veh group. FGK also increased GSH levels, decreased MDA concentrations, suppressed IL-6 expression, and attenuated histopathological alterations in esophageal tissue. FGK demonstrates dose-dependent protective effects against RE-related esophageal damage and inflammation. These findings suggest that FGK may serve as a novel dietary intervention for the prevention and management of acute RE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.